Seagen Inc (SGEN) News Headlines

▮ More

Date

Headline

1/19/2023 9:54:28 PM Seagen : FDA Grants Accelerated Approval To Tukysa Combination For Colorectal Cancer Treatment

1/9/2023 3:00:03 PM Seagen To Present At The J.P. Morgan Healthcare Conference; Webcast At 6:00 PM ET

12/27/2022 4:57:30 AM Biotech Stocks Facing FDA Decision In January 2023

12/20/2022 7:08:25 AM Astellas: PADCEV, KEYTRUDA Granted Priority Review In Treatment Of Metastatic Urothelial Cancer

12/20/2022 6:48:07 AM Astellas : FDA Accepts SBLAs For PADCEV Combination For Treatment Of Metastatic Urothelial Cancer

12/12/2022 10:07:54 AM Seagen Announces Results From Phase 2 Trial Of ADCETRIS With Immunotherapy Combination In Classical Hodgkin Lymphoma

11/10/2022 7:22:27 AM Seagen Appoints David Epstein As New CEO

11/10/2022 7:07:26 AM Seagen Appoints Sandra Swain To Board

11/10/2022 7:04:40 AM Seagen Appoints David Epstein As CEO

10/27/2022 4:12:26 PM Seagen Q3 Loss/share $1.03 Vs. Loss $1.61 Year Ago

10/27/2022 4:09:40 PM Seagen Inc (SGEN) Has Raised Its 2022 Revenue Estimate To $1820 - $1865 Mln From $1710 - $1795 Mln

10/27/2022 4:08:12 PM Seagen Inc Q3 Loss decreases, but misses estimates

10/26/2022 6:00:44 AM Biotech Stocks Facing FDA Decision In November 2022

9/26/2022 8:32:54 AM Seagen, LAVA Therapeutics Ink Worldwide License Agreement To Develop And Commercialize LAVA-1223

9/26/2022 8:06:42 AM Seagen And LAVA Therapeutics Announce Worldwide License Agreement To Develop And Commercialize LAVA-1223

9/19/2022 8:16:23 AM Seagen: FDA To Review SNDA For Tucatinib In Combination With Trastuzumab

9/19/2022 8:05:10 AM Seagen : TUKYSA -Trastuzumab Combination Granted Priority Review By FDA For HER2-Positive Metastatic Colorectal Cancer

9/14/2022 11:57:59 AM Seagen To Present At Morgan Stanley Global Healthcare Conference; Webcast At 12:55 PM ET

9/12/2022 9:26:03 AM Seagen, Astellas, Merck: EV-103 Results Support Investigation Of Enfortumab Vedotin, Pembrolizumab

9/12/2022 9:02:23 AM Astellas Reports Results Of Trial Of PADCEV -KEYTRUDA &PADCEV As Monotherapy In First-Line Advanced Urothelial Cancer